Literature DB >> 15990182

Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay.

Anna Janecka1, Jeroen Poels, Jakub Fichna, Kazimierz Studzian, Jozef Vanden Broeck.   

Abstract

Neurokinin receptors (NK1, NK2, NK3) are G-protein-coupled receptors, which upon activation by a peptide agonist induce a transient increase in the concentration of intracellular calcium. The functional assay based on aequorin-derived luminescence triggered by receptor-mediated changes in Ca2+ levels was used to compare the effect of spantides I-III on SP-, NKA- and NKB-stimulated NK1, NK2 and NK3 receptors, respectively. Recombinant cell lines expressing neurokinin receptors and apoaequorin were used in the study. The obtained results indicate that all three spantides acted as competitive antagonists at the NK1 and NK2 receptors and inhibited agonist-induced calcium responses. The rank order of antagonism at the NK1 receptor was spantide II>spantide III>spantide I and at the NK2 receptor was spantide III>spantide II>spantide I. All three spantides failed to antagonize NKB-induced calcium responses at the NK3 receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990182     DOI: 10.1016/j.regpep.2005.05.006

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

2.  Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice.

Authors:  Joanna Starnowska; Roberto Costante; Karel Guillemyn; Katarzyna Popiolek-Barczyk; Nga N Chung; Carole Lemieux; Attila Keresztes; Joost Van Duppen; Adriano Mollica; John Streicher; Jozef Vanden Broeck; Peter W Schiller; Dirk Tourwé; Joanna Mika; Steven Ballet; Barbara Przewlocka
Journal:  ACS Chem Neurosci       Date:  2017-07-26       Impact factor: 4.418

3.  The lipid-associated 3D structure of SPA, a broad-spectrum neuropeptide antagonist with anticancer properties.

Authors:  David A Keire; Mohanraja Kumar; Weidong Hu; James Sinnett-Smith; Enrique Rozengurt
Journal:  Biophys J       Date:  2006-09-22       Impact factor: 4.033

4.  Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.

Authors:  Karel Guillemyn; Patrycia Kleczkowska; Anna Lesniak; Jolanta Dyniewicz; Olivier Van der Poorten; Isabelle Van den Eynde; Attila Keresztes; Eva Varga; Josephine Lai; Frank Porreca; Nga N Chung; Carole Lemieux; Joanna Mika; Ewelina Rojewska; Wioletta Makuch; Joost Van Duppen; Barbara Przewlocka; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Dirk Tourwé; Steven Ballet
Journal:  Eur J Med Chem       Date:  2014-12-19       Impact factor: 6.514

Review 5.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.